federal regulators canceled a meeting around the company's
experimental drug to treat a debilitating liver condition.
The delayed meeting with the Food and Drug Administration
essentially let loose a domino action: The company's future
clinical trial plans are set back and it must find ways to
reduce its cash burn in the meantime.
https://archive.fo/cHOe2